FR23C1050I1 - COMPOSED OF 3,5-DISUBSTITUTED ALKYNYLBENZENE AND A SALT THEREOF - Google Patents

COMPOSED OF 3,5-DISUBSTITUTED ALKYNYLBENZENE AND A SALT THEREOF

Info

Publication number: FR23C1050I1
Authority: FR; France
Prior art keywords: alkynylbenzene; disubstituted; salt; disubstituted alkynylbenzene
Prior art date: 2012-01-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR23C1050C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Taiho Pharmaceutical Co Ltd

Original Assignee

Taiho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-01-19

Filing date

2023-12-19

Publication date

2024-01-26

2023-12-19 Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd

2024-01-26 Publication of FR23C1050I1 publication Critical patent/FR23C1050I1/en

2024-12-13 Application granted granted Critical

2024-12-13 Publication of FR23C1050I2 publication Critical patent/FR23C1050I2/en

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Oncology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyridine Compounds (AREA)

FR23C1050C 2012-01-19 2023-12-19 COMPOUND OF 3,5-DISUBSTITUTED ALKYNYLBENZENE AND A SALT THEREOF Active FR23C1050I2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2012009467		2012-01-19
PCT/JP2013/050740 WO2013108809A1 (en)	2012-01-19	2013-01-17	3,5-disubstituted alkynylbenzene compound and salt thereof

Publications (2)

Publication Number	Publication Date
FR23C1050I1 true FR23C1050I1 (en)	2024-01-26
FR23C1050I2 FR23C1050I2 (en)	2024-12-13

Family

ID=48799233

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR23C1050C Active FR23C1050I2 (en)	2012-01-19	2023-12-19	COMPOUND OF 3,5-DISUBSTITUTED ALKYNYLBENZENE AND A SALT THEREOF

Country Status (23)

Country	Link
US (1)	US9108973B2 (en)
EP (1)	EP2657233B1 (en)
JP (1)	JP5355825B1 (en)
KR (1)	KR101623286B1 (en)
CN (1)	CN103958512B (en)
AU (1)	AU2013210403B2 (en)
BR (1)	BR112014017749B1 (en)
CA (1)	CA2854093C (en)
DK (1)	DK2657233T3 (en)
ES (1)	ES2516392T3 (en)
FI (1)	FIC20230038I1 (en)
FR (1)	FR23C1050I2 (en)
HU (1)	HUS2300043I1 (en)
MX (1)	MX351513B (en)
MY (1)	MY171055A (en)
NL (1)	NL301254I2 (en)
NO (1)	NO2023046I1 (en)
PL (1)	PL2657233T3 (en)
PT (1)	PT2657233E (en)
RU (1)	RU2576384C1 (en)
SG (1)	SG2014009286A (en)
TW (1)	TWI508964B (en)
WO (1)	WO2013108809A1 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012088266A2 (en)	2010-12-22	2012-06-28	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
JP5873656B2 (en)	2011-06-13	2016-03-01	株式会社Ihi	Metal salen complex compounds, local anesthetics and antineoplastic agents
ES2984771T3 (en)	2012-06-13	2024-10-31	Incyte Holdings Corp	Substituted tricyclic compounds as FGFR inhibitors
RU2019102203A (en)	2012-07-11	2019-03-05	Блюпринт Медсинс Корпорейшн	FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
AR094812A1 (en)	2013-02-20	2015-08-26	Eisai R&D Man Co Ltd	DERIVED FROM MONOCYCLIC PYRIDINE AS AN FGFR INHIBITOR
EA035095B1 (en)	2013-04-19	2020-04-27	Инсайт Холдингс Корпорейшн	Bicyclic heterocycles as fgfr inhibitors
ES2819398T3 (en) *	2013-07-18	2021-04-15	Taiho Pharmaceutical Co Ltd	Therapeutic agent for cancer resistant to the FGFR inhibitor
TWI574691B (en) *	2013-07-18	2017-03-21	Taiho Pharmaceutical Co Ltd	Anti - tumor agents for intermittent administration of FGFR inhibitors
CA2921208C (en)	2013-08-12	2018-02-20	Taiho Pharmaceutical Co., Ltd.	Fused pyrimidine compound or salt thereof
PT3395814T (en)	2013-10-25	2022-07-27	Blueprint Medicines Corp	Inhibitors of the fibroblast growth factor receptor
JP6514645B2 (en)	2013-12-27	2019-05-15	中外製薬株式会社	FGFR Gatekeeper Mutant Gene and Drug Targeting the Same
WO2015108992A1 (en)	2014-01-15	2015-07-23	Blueprint Medicines Corporation	Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
PT3103802T (en) *	2014-06-24	2017-12-11	Taiho Pharmaceutical Co Ltd	Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
US9951047B2 (en)	2014-08-18	2018-04-24	Eisai R&D Management Co., Ltd.	Salt of monocyclic pyridine derivative and crystal thereof
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
CN105837575B (en) *	2015-01-13	2019-01-15	四川大学	3- acetenyl Pyrazolopyrimidine derivative and its preparation method and application
TWI638817B (en) *	2015-01-30	2018-10-21	大鵬藥品工業股份有限公司	Preventive and / or therapeutic agent for immune diseases
MA41551A (en)	2015-02-20	2017-12-26	Incyte Corp	BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
US9580423B2 (en)	2015-02-20	2017-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
EA038045B1 (en)	2015-02-20	2021-06-28	Инсайт Корпорейшн	Bicyclic heterocycles as fgfr inhibitors
EP3275442B1 (en)	2015-03-25	2021-07-28	National Cancer Center	Therapeutic agent for bile duct cancer
CN111393446B (en) *	2015-03-31	2022-12-20	大鹏药品工业株式会社	3, 5-disubstituted phenylalkynyl compound crystal
US10479780B2 (en)	2015-06-17	2019-11-19	Chugai Seiyaku Kabushiki Kaisha	Aminopyrazole derivatives
EP3345907B1 (en) *	2015-09-01	2020-04-22	Taiho Pharmaceutical Co., Ltd.	Pyrazolo[3,4-d]pyrimidine compounds or salts thereof
WO2017104739A1 (en)	2015-12-17	2017-06-22	エーザイ・アール・アンド・ディー・マネジメント株式会社	Therapeutic agent for breast cancer
TWI623316B (en) *	2015-12-22	2018-05-11	Taiho Pharmaceutical Co Ltd	Antitumor effect enhancer derived from pyrrolopyrimidine compound
HRP20200352T1 (en) *	2016-02-23	2020-06-12	Taiho Pharmaceutical Co., Ltd.	NEW CONDENSED PYRIMIDINE COMPOUND OR ITS SALT
US11883404B2 (en) *	2016-03-04	2024-01-30	Taiho Pharmaceuticals Co., Ltd.	Preparation and composition for treatment of malignant tumors
KR20220110859A (en) *	2016-03-04	2022-08-09	다이호야쿠힌고교 가부시키가이샤	Preparation and composition for treatment of malignant tumors
CN107344940B (en) *	2016-05-06	2020-04-21	广东东阳光药业有限公司	BTK inhibitors and their uses
CN107698593A (en) *	2016-08-09	2018-02-16	南京天印健华医药科技有限公司	Heterocyclic compound as FGFR inhibitor
MA47696A (en) *	2017-02-28	2020-01-08	Taiho Pharmaceutical Co Ltd	ANTI-TUMOR ACTIVATOR USING A PYRAZOLO [3,4-D] PYRIMIDINE COMPOUND
AR111960A1 (en)	2017-05-26	2019-09-04	Incyte Corp	CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
JOP20180094A1 (en)	2017-10-18	2019-04-18	Hk Inno N Corp	Heterocyclic compound as a protein kinase inhibito
CN109776544B (en) *	2017-11-15	2022-02-01	上海医药工业研究院	Pyrazolo [3,4-d ] pyrimidine compound and preparation method and application thereof
RU2759746C1 (en)	2018-03-19	2021-11-17	Тайхо Фармасьютикал Ко., Лтд.	Pharmaceutical composition including sodium alkyl sulphate
BR112020017922A2 (en)	2018-03-28	2020-12-22	Eisai R&D Management Co., Ltd.	THERAPEUTIC AGENT FOR HEPATOCELLULAR CARCINOMA
US11174257B2 (en)	2018-05-04	2021-11-16	Incyte Corporation	Salts of an FGFR inhibitor
RS66310B1 (en)	2018-05-04	2025-01-31	Incyte Corp	Solid forms of an fgfr inhibitor and processes for preparing the same
JP7162372B2 (en)	2018-07-02	2022-10-28	深▲チェン▼市塔吉瑞生物医薬有限公司	Alkynyl (hetero)aromatic compounds for inhibiting kinase activity
WO2020096050A1 (en)	2018-11-09	2020-05-14	大鵬薬品工業株式会社	Dimethoxybenzene compound analogs, methods for analyzing said compounds and standard products of said compounds
WO2020095452A1 (en) *	2018-11-09	2020-05-14	大鵬薬品工業株式会社	Method for producing dimethoxybenzene compound
KR102195348B1 (en)	2018-11-15	2020-12-24	에이치케이이노엔 주식회사	Novel compound as a protein kinase inhibitor, and the pharmaceutical composition comprising thereof
EP3888643A4 (en) *	2018-11-26	2022-08-24	Taiho Pharmaceutical Co., Ltd.	THERAPEUTIC AND PROPHYLACTIC METHOD AGAINST AN ENDOCRINOTHERAPY-TREATABLE TUMOR USING A COMBINED USE OF A FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND AN ENDOCRINOTHERAPY
WO2020170355A1 (en) *	2019-02-20	2020-08-27	大鵬薬品工業株式会社	Method for treating fgfr1 mutated tumor
WO2020175704A1 (en) *	2019-02-28	2020-09-03	大鵬薬品工業株式会社	Cancer therapy using 3,5-disubstituted benzene alkynyl compound and immune checkpoint inhibitor
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
KR20210142154A (en)	2019-03-21	2021-11-24	옹쎄오	DBAIT molecules in combination with kinase inhibitors for the treatment of cancer
MX2021013146A (en) *	2019-05-13	2022-01-24	Relay Therapeutics Inc	Fgfr inhibitors and methods of use thereof.
CA3139161A1 (en) *	2019-05-17	2020-11-26	Kinnate Biopharma Inc.	Inhibitors of fibroblast growth factor receptor kinases
EP3988175A4 (en)	2019-06-21	2023-06-28	Taiho Pharmaceutical Co., Ltd.	Method for treating malignant tumor
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
PH12022550892A1 (en)	2019-10-14	2023-05-03	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
CN114761006A (en)	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	Methods of treating cancer resistant to kinase inhibitors
CN114641293B (en) *	2019-11-08	2024-05-31	石药集团中奇制药技术（石家庄）有限公司	Use of a FGFR inhibitor
AU2020395185A1 (en)	2019-12-04	2022-06-02	Incyte Corporation	Derivatives of an FGFR inhibitor
EP4069696A1 (en)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
EP4098263A4 (en)	2020-01-31	2024-03-20	Kyoto University	TREATMENT AGAINST CHONDRODYSTROPHY
CN116057045A (en)	2020-06-05	2023-05-02	金耐特生物制药公司	Fibroblast Growth Factor Receptor Kinase Inhibitors
EP4183395A4 (en) *	2020-07-15	2024-07-24	Taiho Pharmaceutical Co., Ltd.	Pyrimidine compound-containing combination to be used in tumor treatment
TWI797711B (en) *	2020-08-13	2023-04-01	大陸商上海和譽生物醫藥科技有限公司	A kind of FGFR and mutation inhibitor thereof, its preparation method and application
CN115867547B (en) *	2020-08-27	2024-12-20	上海和誉生物医药科技有限公司	1H-pyrazole-4-amide derivative, preparation method and application thereof
TW202233625A (en)	2020-11-18	2022-09-01	美商傳達治療有限公司	Fgfr inhibitors and methods of making and using the same
CA3199714A1 (en) *	2020-11-20	2022-05-27	Isao Miyazaki	Brain-migrating tumor therapeutic agent containing fused pyrimidine compound as active ingredient
CN114805359B (en) *	2021-01-28	2023-10-27	药雅科技(上海)有限公司	Preparation method and application of acetylenic heterocyclic compound FGFR inhibitor
CN115028634B (en) *	2021-03-08	2023-11-28	药雅科技(上海)有限公司	Acetylenic pyrazino heterocycle FGFR inhibitor and preparation method and application thereof
KR20230170668A (en) *	2021-03-08	2023-12-19	다이호야쿠힌고교 가부시키가이샤	Cancer treatment in patients with co-occurring genetic alterations in FGFR2 and oncogenic genes
JP2024513575A (en)	2021-04-12	2024-03-26	インサイト・コーポレイション	Combination therapy including FGFR inhibitor and Nectin-4 targeting agent
WO2022261160A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
TW202313610A (en)	2021-06-09	2023-04-01	美商英塞特公司	Tricyclic heterocycles as fgfr inhibitors
CN115785103A (en) *	2022-12-28	2023-03-14	北京康立生医药技术开发有限公司	Synthetic method of medicine fubatinib for treating bile duct cancer
WO2025178019A1 (en) *	2024-02-19	2025-08-28	国立大学法人大阪大学	Pharmaceutical composition for treating ciliopathy
CN119080780A (en) *	2024-08-29	2024-12-06	武汉九州钰民医药科技有限公司	A preparation method of futibatinib
CN120172981B (en) *	2025-05-20	2025-07-25	南京工业大学	A type of small molecule degradation agent targeting FGFR2 and its pharmaceutical composition and application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007087395A2 (en) *	2006-01-25	2007-08-02	Osi Pharmaceuticals, Inc.	UNSATURATED mTOR INHIBITORS
EA017865B1 (en) *	2007-03-28	2013-03-29	Фармасайкликс, Инк.	Inhibitors of bruton's tyrosine kinase
GB0819105D0 (en) *	2008-10-17	2008-11-26	Chroma Therapeutics Ltd	Pyrrolo-pyrimidine compounds
KR101483215B1 (en) *	2010-01-29	2015-01-16	한미약품 주식회사	Bicyclic heteroaryl derivatives having inhibitory activity for protein kinases
EA201890869A3 (en) *	2010-06-03	2019-03-29	Фармасайкликс, Инк.	APPLICATION OF BLUTON THYROSIN KINASE INHIBITORS (BTK)

2013
- 2013-01-17 AU AU2013210403A patent/AU2013210403B2/en active Active
- 2013-01-17 US US14/344,935 patent/US9108973B2/en active Active
- 2013-01-17 MY MYPI2014700531A patent/MY171055A/en unknown
- 2013-01-17 SG SG2014009286A patent/SG2014009286A/en unknown
- 2013-01-17 CA CA2854093A patent/CA2854093C/en active Active
- 2013-01-17 WO PCT/JP2013/050740 patent/WO2013108809A1/en not_active Ceased
- 2013-01-17 BR BR112014017749-0A patent/BR112014017749B1/en active IP Right Grant
- 2013-01-17 RU RU2014133907/04A patent/RU2576384C1/en active
- 2013-01-17 MX MX2014008605A patent/MX351513B/en active IP Right Grant
- 2013-01-17 PL PL13728918T patent/PL2657233T3/en unknown
- 2013-01-17 PT PT137289187T patent/PT2657233E/en unknown
- 2013-01-17 JP JP2013523428A patent/JP5355825B1/en active Active
- 2013-01-17 KR KR1020147013608A patent/KR101623286B1/en active Active
- 2013-01-17 DK DK13728918.7T patent/DK2657233T3/en active
- 2013-01-17 ES ES13728918.7T patent/ES2516392T3/en active Active
- 2013-01-17 CN CN201380003870.8A patent/CN103958512B/en active Active
- 2013-01-17 EP EP13728918.7A patent/EP2657233B1/en active Active
- 2013-01-18 TW TW102102005A patent/TWI508964B/en active
2023
- 2023-12-18 NL NL301254C patent/NL301254I2/en unknown
- 2023-12-18 FI FIC20230038C patent/FIC20230038I1/en unknown
- 2023-12-19 FR FR23C1050C patent/FR23C1050I2/en active Active
- 2023-12-20 NO NO2023046C patent/NO2023046I1/en unknown
- 2023-12-21 HU HUS2300043C patent/HUS2300043I1/en unknown

Also Published As

Publication number	Publication date
KR101623286B1 (en)	2016-05-20
SG2014009286A (en)	2014-04-28
MX351513B (en)	2017-10-17
ES2516392T3 (en)	2014-10-30
EP2657233B1 (en)	2014-08-27
FR23C1050I2 (en)	2024-12-13
AU2013210403B2 (en)	2016-01-14
BR112014017749B1 (en)	2021-08-03
AU2013210403A1 (en)	2014-06-26
FIC20230038I1 (en)	2023-12-18
CN103958512A (en)	2014-07-30
US9108973B2 (en)	2015-08-18
CA2854093C (en)	2016-07-05
WO2013108809A1 (en)	2013-07-25
BR112014017749A8 (en)	2017-07-11
DK2657233T3 (en)	2014-09-22
EP2657233A1 (en)	2013-10-30
HK1198164A1 (en)	2015-03-13
KR20140080551A (en)	2014-06-30
PL2657233T3 (en)	2015-01-30
MX2014008605A (en)	2014-08-27
NL301254I1 (en)	2023-12-20
RU2576384C1 (en)	2016-03-10
JPWO2013108809A1 (en)	2015-05-11
NL301254I2 (en)	2024-01-10
NO2023046I1 (en)	2023-12-20
PT2657233E (en)	2014-10-24
JP5355825B1 (en)	2013-11-27
US20140343035A1 (en)	2014-11-20
EP2657233A4 (en)	2013-12-04
TW201335156A (en)	2013-09-01
CN103958512B (en)	2016-01-20
MY171055A (en)	2019-09-23
BR112014017749A2 (en)	2017-06-20
HUS2300043I1 (en)	2024-01-28
CA2854093A1 (en)	2013-07-25
TWI508964B (en)	2015-11-21

Publication	Publication Date	Title
FR23C1050I1 (en)	2024-01-26	COMPOSED OF 3,5-DISUBSTITUTED ALKYNYLBENZENE AND A SALT THEREOF
BR302012005333S1 (en)	2014-05-27	"COVER APPLICATION".
CL2014003498A1 (en)	2015-05-08	Fungicidal heterocyclic carboxamides
EP2540716A4 (en)	2013-08-07	TETRAZOLYLOXIME DERIVATIVE OR SALT THEREOF, AND GERMICIDE
EP2601921A4 (en)	2014-04-09	DISPOSABLE CLOTHING
FR2994831B1 (en)	2015-08-21	PROSTHESIS OF HAND.
FR2985500B1 (en)	2017-09-08	HELICOPTER CONFIGURATION
BR112014027025A2 (en)	2017-06-27	Cosmetic makeup.
EP2901300A4 (en)	2016-05-18	DIMENSIONING EXTERNAL IDENTIFIERS
CL2014003459A1 (en)	2015-08-28	Heterocyclic fungicidal compounds.
IT1398747B1 (en)	2013-03-18	OSCILLATOR.
EP2738163A4 (en)	2014-12-10	AMIDINE COMPOUND OR SALT THEREOF
PL2817297T3 (en)	2016-06-30	Herbicidally active 3-(sulfinylamino)-benzamides
FR2984087B1 (en)	2014-05-23	COSMETIC APPLICATION ELEMENT.
EP2847717A4 (en)	2015-12-16	SOCIAL INTELLIGENCE ARCHITECTURE
BR112013031570A2 (en)	2017-03-21	dry powder inhaler.
CL2015001192A1 (en)	2015-08-28	Herbicidal composition
BR302012006162S1 (en)	2014-12-09	"CARTRIDGE CONFIGURATION"
EP2912257A4 (en)	2016-11-23	ADVANCED ERUPTION VALVE
FR2990456B1 (en)	2015-04-10	PREFABRICATED STAIRWALK
FR2987772B1 (en)	2015-04-17	ROBOTISE CASE LOADER
FR2992202B1 (en)	2014-07-18	DIRECT COSMETIC EMULSION.
TH1501000684B (en)	2016-11-29	The ladle receives each living creature.
BR302012003604S1 (en)	2014-11-11	"CAPSULE CONFIGURATION"
BR302012003605S1 (en)	2013-12-17	"CAPSULE CONFIGURATION"